Chembio Diagnostics Inc, Medford, NY, has announced plans to commercialize multiple combination dual-path platform (DPP) malaria assays to identify Plasmodium falciparum and other Plasmodium infections.
The company’s family of DPP malaria assays will include the DPP malaria-ebola assay that the company developed under a research collaboration agreement with the US Centers for Disease Control and Prevention (CDC), and a DPP fever panel assay to be developed by Chembio under a 12-month grant from the Paul G. Allen ebola program.
The company recently completed an externally funded project comparing its DPP malaria assay, developed during the first half of 2015, to the world’s leading currently available POC malaria assay.
Javan Esfandiari, Chembio.
“The results of Chembio’s malaria feasibility work demonstrate the advantages of our DPP technology in providing the high sensitivity required to identify the parasite infection at very low levels,” says Javan Esfandiari, chief science and technology officer at Chembio. “In only 6 months, we created a DPP malaria assay that can compete against the world’s leading point-of-care malaria products.”
John J. Sperzel III, Chembio Diagnostic Systems.
“We are extremely pleased with the performance of the DPP malaria assay and believe it will provide healthcare workers with a new advantage in fighting this serious fever disease,” says John Sperzel, CEO of Chembio. “Based on these results, we are aggressively working toward the development and launch of a new suite of DPP malaria assays, including DPP malaria-ebola assay, which we expect to begin field testing in West Africa in 2015, and DPP fever panel assay (chikungunya, dengue, Ebola, Lassa, malaria, and Marburg), which is expected to be ready for field testing in 12 months.”
For more information, visit Chembio Diagnostics.
